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Summary
The prevalence of gestational diabetes is 
increasing in Australia. Non-pharmacological 
intervention with dietary measures and exercise is 
the mainstay of therapy in most cases, but insulin 
is increasingly necessary to achieve adequate 
glycaemic control in some women. Basal-bolus 
insulin is the optimal management strategy, but 
therapy needs to be individualised. Although there 
is mounting evidence for the efficacy and safety 
of metformin, the lack of long-term follow-up data 
has prevented it from being recommended by 
most experts in the field. women with gestational 
diabetes need long-term follow-up because of 
their increased risk of type 2 diabetes.
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Introduction
Gestational diabetes is defined as an intolerance to glucose  
that is first diagnosed or has its onset during pregnancy. It is 
estimated to affect almost 5% of pregnancies in Australia and 
between 3% and 9% worldwide. Its prevalence increases with 
age, from 1% in women aged 15–19 years to 13% in those 
aged 44–49 years.1 Other risk factors for developing gestational 
diabetes include being overweight or obese, having a family 
history of type 2 diabetes or a personal or family history of 
gestational diabetes or glucose intolerance, being from an 
Aboriginal or Torres Strait Islander background or belonging to 
certain ethnic groups (for example Polynesian, Middle Eastern, 
Indian or other Asian origin).2 Although gestational diabetes 
does not affect perinatal mortality, it does increase morbidity, 
including the risk of shoulder dystocia, nerve palsies and 
neonatal hypoglycaemia. Maternal outcomes are also affected, 
with a higher incidence of pre-eclampsia and caesarean section 
(particularly with poor glycaemic control) in mothers who 
develop gestational diabetes.3
Diagnosis
Universal screening for gestational diabetes has been 
recommended in Australia since 1998. A fasting glucose challenge 
test should be performed at 26–28 weeks gestation. If abnormal, 
this is followed by a formal two-hour 75 g oral glucose tolerance 
test. Criteria for diagnosis are presented in Table 1. For women 
at risk of gestational diabetes, a glucose tolerance test can be 
performed at any stage during pregnancy. However, as placental 
production of diabetogenic hormones tends to increase throughout 
the second and third trimesters, a normal glucose tolerance test 
in the early part of pregnancy does not exclude the development 
of gestational diabetes later on. A second oral glucose tolerance 
test should therefore be performed at the standard 26–28 weeks of 
gestation even if an earlier test was normal.
New recommendations for screening and diagnosis are currently 
under consideration, but have yet to be adopted or approved by 
expert groups in gestational diabetes. It is likely, however, that 
the glucose challenge test will be removed from the screening 
process, so that a diagnosis of gestational diabetes will be made 
if the blood glucose is abnormal when fasting, or one or two 
hours after a 75 g glucose load (see Table 1).
Blood glucose targets
Once diagnosed, all women need to be educated about the 
possible implications of gestational diabetes (both fetal and 
maternal) and be taught how to perform home blood glucose 
monitoring. Finger-prick testing should be performed four times  
Table 1
Current and possible future diagnostic criteria for 
gestational diabetes 
Test Venous plasma glucose 
– for diagnosis
Current 
practices
screen:
non-fasting 
50 g glucose 
challenge 
1 hour ≥ 7.8 mmol/L  
(requires confirmatory 
testing)
confirmatory 
testing:
fasting 75 g  
glucose 
tolerance 
one of either:
n fasting ≥ 5.5 mmol/L
 or
n 2 hour ≥ 8.0 mmol/L
Potential 
new  
criteria13
fasting 75 g 
oral glucose 
tolerance 
any one of three:
n fasting ≥ 5.1 mmol/L
n 1 hour ≥ 10.0 mmol/L
n 2 hour ≥ 8.5 mmol/L
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a day (before breakfast and two hours after each meal). Target 
blood glucose concentrations, shown in Table 2, need to be 
explained. 
The results of the Hyperglycemia and Adverse Pregnancy 
Outcomes trial have demonstrated that the risks associated with 
maternal hyperglycaemia are on a continuum above the normal 
blood glucose concentration and treatment targets might be 
lowered in the future to reflect this.4 As yet, a consensus on 
where these targets will be set has not been established.
Non-pharmacological interventions
All women with gestational diabetes should receive advice 
from a dietitian with specific knowledge in the area and dietary 
intervention should be initial therapy for most women. Dietary 
advice needs to be individualised, taking into account factors 
such as the patient's body mass index (BMI) and overall 
nutritional requirements.2 Care should be taken to avoid 
excessive caloric restriction, as this can result in ketonuria and 
adverse pregnancy outcomes.5 Moderate intensity exercise, 
such as a brisk walk for 30 minutes each day, can decrease 
insulin resistance and should be encouraged.6
Insulin 
Insulin therapy remains the mainstay of pharmacotherapy and 
its use is becoming increasingly prevalent. In 2005–06, about 
30% of confinements with gestational diabetes were treated 
with insulin, with women in older age groups requiring it in 
about 40% of cases.1 Insulin should be considered when blood 
glucose concentrations (Table 2) exceed recommended targets 
on two or more occasions within one week. The indication for 
starting insulin is stronger if there is evidence of macrosomia or 
increased fetal abdominal circumference.2
All women started on insulin need education regarding storage 
of insulin, correct injection technique as well as recognition 
and treatment of hypoglycaemia. The assistance of a diabetes 
educator with this can be invaluable.
Insulin therapy needs to be individualised and is dependent 
upon the patient's blood glucose concentrations, her weight and 
her wishes. The regimen is determined by whether the blood 
glucose is elevated when fasting, after a meal, or both. 
Elevated fasting glucose
If the fasting glucose is elevated, but postprandial levels are within 
the recommended target range, a single bedtime injection of 
intermediate-acting insulin (for example insulin isophane) will often 
suffice. A starting dose of 4–12 units is reasonable. If postprandial 
hyperglycaemia occurs later in the pregnancy, mealtime injections 
of rapid-acting insulin may need to be introduced.
Postprandial hyperglycaemia 
Occasionally, women may have elevated postprandial blood 
glucose with normal fasting levels. Dietary intervention can be 
useful in this situation. However, should this prove inadequate, 
mealtime injections of rapid-acting insulin (for example insulin 
aspart, insulin lispro) can be introduced. Starting doses of 4–8 
units with each meal are reasonable. Soluble human insulin 
is an alternative, but has the disadvantage of needing to be 
injected 30 minutes before eating.
Fasting and postprandial hyperglycaemia
A basal-bolus insulin regimen (mealtime rapid-acting insulin and 
bedtime intermediate-acting insulin) is generally preferred as it 
provides the patient with greater flexibility in diet and exercise. 
Twice-daily mixed insulin (for example insulin aspart/protamine 
or lispro/protamine) is an alternative, particularly if the patient is 
reluctant to inject four times per day or might find it too difficult.
Dosing
Larger doses of insulin are reserved for those with higher BMI or 
blood glucose readings significantly above target. Smaller doses 
might be appropriate for women with a slighter build. The dose can 
be titrated every two to three days as required, with increments of 
2–4 units (no greater than 20% dose increase) until targets are met 
or the patient develops excessive hypoglycaemia (more than two to 
three times per week or any episode of severe hypoglycaemia). 
It remains unclear if maternal hypoglycaemia adversely affects 
the fetus. If there are concerns, it tends to be in women with 
pre-existing diabetes in the first trimester of pregnancy (during 
organogenesis)7 and not in those with gestational diabetes.
Insulin doses may be anticipated to rise throughout the third 
trimester as a result of increasing maternal insulin resistance. 
This tends to reach a plateau at 36–38 weeks.
Insulin analogues
There is currently little evidence to support the use of other 
insulin analogues (for example insulin glargine, insulin detemir) 
in pregnancy, although their use is increasing.
Metformin
There is increasing evidence for the use of metformin in 
pregnancy. The Metformin in Gestational Diabetes (MiG) trial, 
an open-label randomised controlled trial comparing metformin 
with insulin, was conducted throughout Australia and New 
Zealand.8 It showed the efficacy and safety of metformin in 
the second and third trimesters with no difference in perinatal 
complications between treatments. Not surprisingly, patients 
Table 2 
Target blood glucose concentrations in gestational 
diabetes 
Blood glucose (mmol/L)
Fasting capillary < 5.5 
Postprandial capillary < 7.0 (2 hours)
< 8.0 (1 hour)
| VOLUME 33 | NUMBER 5 | OCTOBER 2010 143www.austral ianprescriber.com
preferred oral metformin to insulin injections. Almost half of 
the patients taking metformin also required insulin to achieve 
treatment targets. There does not appear to be an increase in 
the risk of congenital malformations, even when the fetus is 
exposed to metformin in the first trimester. 
Although this is promising, there is no long-term follow-
up of children born to mothers who took metformin during 
pregnancy. The use of metformin in pregnancy is therefore not 
currently endorsed by regulatory authorities or professional 
bodies, including the Australian Diabetes in Pregnancy 
Society. Although no adverse effects have been demonstrated, 
metformin does cross the placenta, leading authorities to 
be very cautious in their recommendations. Nonetheless, 
metformin is used for the treatment of gestational diabetes in 
many centres around Australia and New Zealand, but has found 
much less favour in Europe and the USA.
Metformin could be considered for use in patients who have 
failed non-drug therapies and who either refuse or are unable to 
take insulin. The mother should be educated about the potential 
risks, benefits and areas of uncertainty so that an informed 
decision can be made.
Sulfonylureas
Glibenclamide has the most evidence for use in pregnancy. 
Unlike the older sulfonylureas, glibenclamide does not appear 
to cross the placenta to a significant degree. There does 
not appear to be an increase in fetal complications, but, like 
metformin, it is currently not recommended for widespread 
use in pregnancy because of a lack of long-term follow-up of 
children exposed to glibenclamide in utero. 
There is little evidence for the safety or efficacy of other 
sulfonylureas in pregnancy and their use is not recommended. 
Other drugs
There are few data about the safety or efficacy of acarbose, 
thiazolidinediones or incretin mimetics and enhancers in 
pregnancy. Currently these drugs are not recommended and 
their use in pregnancy should be considered experimental.
Follow-up and prognosis
Gestational diabetes resolves postpartum in more than 90% of 
women. In general, all insulin and oral hypoglycaemic drugs are 
ceased immediately postpartum with ongoing blood glucose 
monitoring until discharge from hospital. If concentrations 
return to normal, which occurs in the overwhelming majority 
of cases, a repeat glucose tolerance test should be performed 
6–8 weeks postpartum to ensure that the patient does not have 
overt type 2 diabetes. 
The long-term risk for developing type 2 diabetes is increased 
over sevenfold in women who develop gestational diabetes 
compared with those who have a normoglycaemic pregnancy.9 
Women with a pre-pregnancy BMI of more than 27 kg/m2, those 
of advancing maternal age and those who required insulin for 
glycaemic control in pregnancy are at particularly increased 
risk.10 It is important to counsel women about these issues and 
the need to continue with dietary measures, regular exercise 
and attempts at achieving and maintaining a normal body 
weight long into the future. Both intensive lifestyle intervention 
and drug therapy (metformin) may be useful to decrease the 
risk of these patients developing type 2 diabetes.11
There are no evidence-based guidelines for long-term follow-
up of mothers with gestational diabetes. Australian guidelines 
recommend a glucose tolerance test at least every two years,2 
while others believe that a fasting glucose test one to two yearly 
is sufficient. A more intensive follow-up regimen would be 
rational if the patient has evidence of impaired glucose tolerance 
or impaired fasting glucose on early postnatal testing, a strong 
family history of type 2 diabetes, or if there are other major risk 
factors such as marked obesity or polycystic ovary syndrome.
Children and adolescents whose mothers had gestational diabetes 
seem to be at higher risk of developing features of metabolic 
syndrome compared with mothers who do not have diabetes. 
Although unproven, it is likely that these children will also have a 
higher risk of developing type 2 diabetes as adults.12
Conclusion
Gestational diabetes is increasing in Australia. Appropriate 
screening, diagnosis and management is important, not only 
to improve perinatal and maternal outcomes, but also because 
it may help to decrease the incidence of type 2 diabetes in the 
future. Insulin remains the mainstay of pharmacotherapy, but 
there is increasing use of oral hypoglycaemic drugs (particularly 
metformin) in Australia and New Zealand.
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Avoiding wastage with insulin prescribing
The Pharmaceutical Benefits Scheme (PBS) provides affordable 
medicines to all Australians. However, increasing costs of 
medications are threatening it.
New means of cost-effective and cost-minimising interventions 
are always needed to ensure sustainability and viability of the 
scheme.1 A practical and simple approach of saving is to change 
the PBS listing of insulin prescribed for gestational diabetes and 
users of low-dose insulin who will not necessarily go through 
the normal quantity of insulin provided to them. The standard 
quantity of insulin supplied by the PBS is five boxes of five 
individually packed units. This amount is usually excessive for 
patients using small doses of insulin who are prescribed other 
antidiabetic medicines.
A new listing of a single box of five individually packed units 
made available to these groups of patients will significantly save 
costs to the PBS and promote the quality use of medicines to 
the consumer as well as the prescribers.
By avoiding wastage of medications and educating prescribers 
about the need to restrict supply of excess unnecessary 
medications, resources could be freed up for other government-
funded health expenditures.2
Hanan Khalil 
Senior Lecturer/Pharmacist Academic 
Department of Rural and Indigenous Health 
Monash University, Melbourne
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